Acurx Pharmaceuticals Inc. has announced progress in advancing a new class of antibiotics to Phase 3 trials, targeting WHO and CDC "Priority Pathogens" while addressing growing concerns related to antimicrobial resistance $(AMR)$. The company's lead antibiotic program, ibezapolstat, is designed to treat _C. difficile_ Infection (CDI) and has demonstrated promising results with a 96% cure rate and no recurrence at 30 and 90-day follow-ups during Phase 2 trials. The antibiotics work by targeting the polymerase IIIC enzyme, a novel mechanism of action that has shown clinical validation. Additionally, Acurx Pharmaceuticals is preparing to evaluate ibezapolstat in patients with multiple recurrences of CDI and resistance to current standards of care. The company's commercial supply is manufactured in the U.S., maintaining a "Made In America" policy. Acurx Pharmaceuticals holds $6.1 million in cash on hand. You can access the full presentation through the link below.